Core Insights - Arcutis Biotherapeutics, Inc. has completed enrollment in its INTEGUMENT-INFANT Phase 2 trial for ZORYVE cream 0.05% targeting infants with mild to moderate atopic dermatitis [1][3] Company Overview - ZORYVE is a topical PDE4 inhibitor and is recognized as the leading branded therapy for atopic dermatitis, seborrheic dermatitis, and plaque psoriasis [3] - The cream works by blocking PDE4, which reduces pro-inflammatory mediators, thereby calming skin inflammation and restoring immune balance [3] Clinical Trial Details - The INTEGUMENT-INFANT study is an open-label, multicenter Phase 2 trial assessing the safety and tolerability of ZORYVE cream 0.05% over a four-week period involving 101 infants [3] - Topline data from this study is anticipated to be available in Q1 2026 [3] Market Context - Atopic dermatitis affects nearly 9.6 million children in the U.S., with up to 60% showing symptoms within their first year of life [2] - ZORYVE cream 0.05% was approved in October 2025 for children aged 2 to 5 years, providing a steroid-free alternative to corticosteroids for mild to moderate atopic dermatitis [4] Stock Performance - ARQT's stock has fluctuated between $8.90 and $27.08 over the past year, closing at $22.86, down 2.52%, but rebounding to $23.51 in overnight trading, up 2.84% [5]

Core Insights - The FDA has approved Arcutis Biotherapeutics' ZORYVE (roflumilast) cream 0.05% for treating mild to moderate atopic dermatitis in children aged 2 to 5 years, providing a steroid-free alternative for long-term use [1][6][23] - Approximately 1.8 million children in the U.S. aged 2 to 5 are treated for atopic dermatitis, highlighting a significant market need for effective treatments [2][6] - ZORYVE cream demonstrated rapid and significant improvements in clinical trials, with 40% of children achieving a 75% improvement in eczema symptoms within four weeks [2][12] Company Overview - Arcutis Biotherapeutics is focused on developing innovative treatments for immune-mediated dermatological diseases, with a growing portfolio of advanced topical therapies [30] - The approval of ZORYVE cream 0.05% marks the sixth FDA approval for the ZORYVE product line in just over three years, indicating strong regulatory momentum [1][6] - The company aims to ensure predictable access to ZORYVE through patient support programs, including the ZORYVE Direct Program and Arcutis Cares™ for financially eligible patients [4][30] Clinical Data - The FDA approval was based on results from the INTEGUMENT-PED Phase 3 trial, which involved 652 children and demonstrated rapid disease clearance and safety [10][11] - In the INTEGUMENT-PED trial, 25.4% of children treated with ZORYVE achieved a 'Clear' or 'Almost Clear' status by Week 4, compared to 10.7% in the vehicle group [12] - The long-term extension study (INTEGUMENT-OLE) showed that 71.9% of participants maintained a 75% improvement in eczema severity after 56 weeks of treatment [16] Market Context - Atopic dermatitis affects approximately 9.6 million children in the U.S., with a significant impact on family life due to sleep disruption and emotional distress [19][20] - ZORYVE is positioned as a leading topical therapy for atopic dermatitis, with recognition from industry awards, including Allure's "2025 Best of Beauty Breakthrough Award" [22][21] - The product's formulation targets underlying inflammation without compromising the skin barrier, making it particularly suitable for young children [3][21]

Core Insights - Arcutis Biotherapeutics, Inc. is presenting five posters at the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference, showcasing new data on the long-term safety and efficacy of ZORYVE cream in treating atopic dermatitis (AD) in children aged 2 to 5 [1][2] Group 1: Study Findings - The INTEGUMENT-OLE study demonstrated that ZORYVE cream 0.05% has long-term safety and durable efficacy in children aged 2 to 5 with AD, with a median duration of disease control of 238 days for those switching to a proactive twice-weekly application [2][5] - In the study, 32.7% of participants aged 6 years and older and 28.8% of participants aged 2 to 5 achieved a validated Investigator Global Assessment (vIGA-AD) score of clear or almost clear by Week 4, improving to 55.7% and 63.1% respectively by Week 52 [3][5] - Significant improvements in itch were observed, with 30.9% of participants aged 6 years and older and 41.2% of participants aged 2 to 5 achieving a clinically meaningful reduction in itch at the conclusion of the parent studies, improving to 55.3% and 60.7% respectively after up to 56 weeks of treatment [3][5] Group 2: Clinical Implications - The data highlight the critical need for effective, long-term, steroid-free treatment options for young children with AD, as chronic use of topical steroids can lead to significant adverse events [4][5] - ZORYVE cream formulations were well tolerated, with treatment-related adverse events reported in 4.7% of participants aged 6 years and older and 2.5% of participants aged 2 to 5 [4][5] - The investigational ZORYVE cream 0.05% is currently under FDA review, with a target action date of October 13, 2025, indicating potential for future market introduction [13]